See the DrugPatentWatch profile for apixaban
What does DrugPatentWatch list for apixaban (Eliquis) patents?
DrugPatentWatch tracks patent and exclusivity information tied to branded and generic drug approvals. For apixaban (marketed as Eliquis), its database entry is typically used to identify key patent “expiration” dates and related legal or regulatory milestones that can affect when generic or biosimilar competition is expected to start.
You can check the current apixaban coverage directly here: https://www.drugpatentwatch.com/patent/bms-ef-203-vidya/apixaban/ [1]
When would generic apixaban be expected to launch based on patents?
DrugPatentWatch is commonly used for timeline planning because it aggregates patent-expiry and exclusivity data. The practical answer to “when generic apixaban can launch” depends on:
- which specific patents are still in force,
- whether any are carved out via settlements or litigation outcomes, and
- what regulatory exclusivities apply (separate from patents).
DrugPatentWatch’s apixaban page is the place to see the specific expiration dates it lists and any related events tied to those dates. [1]
Are there patent challenges or litigation tied to apixaban?
Patent exclusivity and “entry timing” often hinge on whether companies challenge listed patents, win, or settle. DrugPatentWatch often helps users spot these potential constraints by tying patent data to the underlying regulatory pathway and any events it records for a product. For apixaban, start with the event and patent list shown on its DrugPatentWatch page. [1]
Why patent expiry dates can differ from “market availability” dates
Even after a patent expiry date, commercial entry can lag due to:
- regulatory review timelines,
- manufacturing/launch readiness,
- ongoing litigation that changes when a generic is cleared to market, and
- remaining patents covering formulation, dosing, or related claims.
DrugPatentWatch helps illustrate which specific patents are active and what dates they show for apixaban. [1]
Sources
- DrugPatentWatch – apixaban patent/exclusivity page